Statin Use is Associated with a Lower Risk of Multiple Myeloma:A Systematic Review and Meta-analysis

Publication date: Available online 26 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ben Ponvilawan, Nipith Charoenngam, Thanitsara Rittiphairoj, Patompong Ungprasert
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Florent Malard, Mohamad Mohty
Source: The Lancet - Category: General Medicine Source Type: research
17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells. Oncol Rep. 2020 Mar 26;: Authors: Zuo Y, Xu H, Chen Z, Xiong F, Zhang B, Chen K, Jiang H, Luo C, Zhang H Abstract Breast cancer is one of the most common malignancies that threaten the health of women. Although there are a few chemotherapies for the clinical treatment of breast cancer, these therapies are faced with the problems of drug‑resistance and metastasis. Drug combination can help to reduce the adverse side effects of chemotherapies using single drugs, and ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Publication date: Available online 26 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ben Ponvilawan, Nipith Charoenngam, Thanitsara Rittiphairoj, Patompong Ungprasert
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Data on receipt of statins and risk of multiple myeloma (MM) are still conflicting. We performed a systematic review that comprised terms for “statin” and “multiple myeloma” and identified 10 eligible studies for meta-analysis. The risk of MM was significantly lower among statin recipients than those who did not receive statins.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Data on statin use and risk of multiple myeloma is still conflicting. We performed a systematic review that comprised of terms for “statin” and “multiple myeloma” and identified 10 eligible studies for meta-analysis. The risk of multiple myeloma was significantly lower among statin-users than non-users with the pooled odds ratio of 0.80 (95% CI, 0.68 – 0.93; I2 = 72%).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Yi He†, Wenyong Long† and Qing Liu* Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Multiple Myeloma (MM) is a disease of malignant plasma cells for which if left untreated, patients face a 6 month median survival (Osgood, 1960). New agents and combinations continue to improve MM outcomes, extending the median survival to 5 years; however, patients will ultimately succumb to the disease after exhausting treatment options (Fonseca et al., 2017). A novel class of drugs, BH3 mimetics, specifically inhibit the gatekeepers of apoptosis known as pro-survival BCL2 family members BCL2, MCL1 and BCL-xL (Figure 1A). BCL-2 selective BH3 mimetic, venetoclax (ABT-199), has shown promise in a subset of MM patients; how...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research
Conclusion The incidence of CVEs and the frequency of asymptomatic PAD in this population was low, and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes might have contributed to the findings. Further prospective and adequately powered studies are needed to explore the effect of the cardiovascular risk profile on CVEs in CML patients taking nilotinib. Micro-Abstract The present study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long-term exposure to ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The incidence of CVEs and frequency of asymptomatic PAD in this population was low and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes, might have contributed to the result. Further prospective and adequately powered studies are needed to explore the effect of cardiovascular risk profile on CVEs in CML patients on Nilotinib. Teaser This study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long term exposure to Nilotinib. By considering the...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Cholesterol | Leukemia | Lymphoma | Myeloma | Statin Therapy